Skip to main content

New directions in psychiatric drug development: promising therapeutics in the pipeline.

Publication ,  Journal Article
Brady, LS; Lisanby, SH; Gordon, JA
Published in: Expert Opin Drug Discov
2023

INTRODUCTION: Psychiatric disorders are a leading cause of disability worldwide, calling for an urgent need for new treatments, early detection, early intervention, and precision medicine. Drug discovery and development in psychiatry continues to expand in new and exciting areas, with several new medications approved for psychiatric indications by the U.S. Food and Drug Administration (FDA) in the last 5 years. AREAS COVERED: In this review, the authors summarize recent new drug approvals and new molecular mechanisms in Phase 1-3 clinical development for psychiatric disorders. Advances in human genetics-driven target identification, emergent technologies such as artificial intelligence-enabled drug discovery, digital health technologies, and biomarker tools and strategies for testing novel mechanisms are highlighted. EXPERT OPINION: There continues to be a need for research focused on understanding the natural history, developmental trajectory, and pathophysiology of psychiatric disorders to identify new molecular and circuit-based targets. Looking to the future, a vision of precision psychiatry is emerging, taking advantage of advances in genetics, digital technology, and multimodal biomarkers to accelerate the development of next-generation therapies for individuals living with mental illnesses.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Expert Opin Drug Discov

DOI

EISSN

1746-045X

Publication Date

2023

Volume

18

Issue

8

Start / End Page

835 / 850

Location

England

Related Subject Headings

  • Precision Medicine
  • Pharmacology & Pharmacy
  • Mental Disorders
  • Humans
  • Drug Discovery
  • Biomarkers
  • Artificial Intelligence
  • 3214 Pharmacology and pharmaceutical sciences
  • 1115 Pharmacology and Pharmaceutical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Brady, L. S., Lisanby, S. H., & Gordon, J. A. (2023). New directions in psychiatric drug development: promising therapeutics in the pipeline. Expert Opin Drug Discov, 18(8), 835–850. https://doi.org/10.1080/17460441.2023.2224555
Brady, Linda S., Sarah H. Lisanby, and Joshua A. Gordon. “New directions in psychiatric drug development: promising therapeutics in the pipeline.Expert Opin Drug Discov 18, no. 8 (2023): 835–50. https://doi.org/10.1080/17460441.2023.2224555.
Brady LS, Lisanby SH, Gordon JA. New directions in psychiatric drug development: promising therapeutics in the pipeline. Expert Opin Drug Discov. 2023;18(8):835–50.
Brady, Linda S., et al. “New directions in psychiatric drug development: promising therapeutics in the pipeline.Expert Opin Drug Discov, vol. 18, no. 8, 2023, pp. 835–50. Pubmed, doi:10.1080/17460441.2023.2224555.
Brady LS, Lisanby SH, Gordon JA. New directions in psychiatric drug development: promising therapeutics in the pipeline. Expert Opin Drug Discov. 2023;18(8):835–850.

Published In

Expert Opin Drug Discov

DOI

EISSN

1746-045X

Publication Date

2023

Volume

18

Issue

8

Start / End Page

835 / 850

Location

England

Related Subject Headings

  • Precision Medicine
  • Pharmacology & Pharmacy
  • Mental Disorders
  • Humans
  • Drug Discovery
  • Biomarkers
  • Artificial Intelligence
  • 3214 Pharmacology and pharmaceutical sciences
  • 1115 Pharmacology and Pharmaceutical Sciences